Editorial Comment to Predictive factors of survival outcomes in first-line therapy for metastatic castration-resistant prostate cancer

被引：0
|
作者：
Yuasa, Takeshi [1 ]
机构：
[1] Canc Inst Hosp, Japanese Fdn Canc Res, Dept Urol, Tokyo, Japan
来源：
INTERNATIONAL JOURNAL OF UROLOGY | 2022年 / 29卷 / 01期
关键词：
MEN;
D O I：
10.1111/iju.14725
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：33 / 33
页数：1
相关论文
共 50 条
  • [41] First-line treatment of metastatic castration-resistant prostate cancer: the real-world Italian cohort of the Prostate Cancer Registry
    Galli, Luca
    Chiuri, Vincenzo Emanuele
    Di Lorenzo, Giuseppe
    Pisconti, Salvatore
    Rossetti, Sabrina
    Sirotova, Zuzana
    Muto, Andrea
    Petrioli, Roberto
    De Tursi, Michele
    Sbrana, Andrea
    Francolini, Giulio
    Ardizzoia, Antonio
    Scavelli, Claudio
    Satta, Francesco
    Quadrini, Silvia
    Airoldi, Mario
    D'Aniello, Carmine
    Bonetti, Andrea
    Conforti, Serafino
    Aieta, Michele
    Beccaglia, Patrizia
    Maestri, Antonio
    Fratino, Lucia
    TUMORI JOURNAL, 2023, 109 (02): : 224 - 232
  • [42] First-Line Treatment After the Failure of Androgen Deprivation Therapy for Non-Metastatic, Castration-Resistant Prostate Cancer Men
    Zhu, Yuhong
    Yang, Gaojie
    Ding, Yangyang
    Wu, Lifen
    INTERNATIONAL JOURNAL OF PHARMACOLOGY, 2022, 18 (04) : 714 - 720
  • [43] Re: Clinical Outcomes in Octogenarians Treated with Docetaxel as First-Line Chemotherapy for Castration-Resistant Prostate Cancer
    Griebling, Tomas L.
    JOURNAL OF UROLOGY, 2017, 197 (01): : 155 - 156
  • [44] Survival Outcomes of Concurrent Treatment with Docetaxel and Androgen Deprivation Therapy in Metastatic Castration-Resistant Prostate Cancer
    Jang, Ho Seong
    Koo, Kyo Chul
    Cho, Kang Su
    Chung, Byung Ha
    YONSEI MEDICAL JOURNAL, 2016, 57 (05) : 1070 - 1078
  • [45] Re: First-Line Treatment in Senior Adults with Metastatic Castration-Resistant Prostate Cancer: A Prospective International Registry
    Griebling, Tomas L.
    JOURNAL OF UROLOGY, 2017, 197 (01): : 157 - 157
  • [46] Role of the neutrophil/lymphocyte ratio in patients with metastatic castration-resistant prostate cancer treated first-line with abiraterone
    Nieblas-Toscano, D.
    Arenas-Bonilla, A. J.
    Flores-Martin, J. F.
    Gutierrez-Tejero, F.
    Velarde-Munoz, C.
    Ramos-Alaminos, C., I
    Salas-Moreno, M. C.
    Galisteo-Moya, R.
    Moreno-Jimenez, J.
    ACTAS UROLOGICAS ESPANOLAS, 2020, 44 (03): : 164 - 171
  • [47] Outcomes Among African American and Non-Hispanic White Men With Metastatic Castration-Resistant Prostate Cancer With First-Line Abiraterone
    Marar, Mallika
    Long, Qi
    Mamtani, Ronac
    Narayan, Vivek
    Vapiwala, Neha
    Parikh, Ravi B.
    JAMA NETWORK OPEN, 2022, 5 (01)
  • [48] Survival beyond cabazitaxel for metastatic castration-resistant prostate cancer
    Blas, Leandro
    Shiota, Masaki
    Tanegashima, Tokiyoshi
    Kobayashi, Satoshi
    Matsumoto, Takashi
    Eto, Masatoshi
    INTERNATIONAL JOURNAL OF UROLOGY, 2024, 31 (07) : 829 - 831
  • [49] Re: Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2021, 206 (01): : 158 - 159
  • [50] Metastatic castration-resistant prostate cancer
    Henriques, Vanessa
    Wenzel, Mike
    Demes, Melanie-Christin
    Koellermann, Jens
    PATHOLOGE, 2021, 42 (04): : 431 - 438
12345